Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies
Authors
Keywords
Ceftazidime, Ceftaroline, Sick Sinus Syndrome, Ceftaroline Fosamil, Single Ascend Dose
Journal
CLINICAL DRUG INVESTIGATION
Volume 35, Issue 5, Pages 307-317
Publisher
Springer Nature
Online
2015-03-27
DOI
10.1007/s40261-015-0283-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers
- (2015) Antoine Tarral et al. CLINICAL THERAPEUTICS
- Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model
- (2013) Seth T. Housman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial
- (2013) Christopher Lucasti et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The rise of carbapenem resistance in Europe: just the tip of the iceberg?
- (2013) Anna-Pelagia Magiorakos et al. Antimicrobial Resistance and Infection Control
- ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa
- (2012) Jared L. Crandon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β-Lactamases and Methicillin-Resistant Staphylococcus aureus Carrying Various Staphylococcal Cassette ChromosomemecTypes
- (2012) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Carbapenemases in Klebsiella pneumoniae and Other Enterobacteriaceae: an Evolving Crisis of Global Dimensions
- (2012) L. S. Tzouvelekis et al. CLINICAL MICROBIOLOGY REVIEWS
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
- (2012) José A. Vazquez et al. CURRENT MEDICAL RESEARCH AND OPINION
- Current Epidemiology and Growing Resistance of Gram-Negative Pathogens
- (2012) David M. Livermore KOREAN JOURNAL OF INTERNAL MEDICINE
- Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases
- (2011) P. R. S. Lagacé-Wiens et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae
- (2011) Z. Aktaş et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Current Concepts in Antimicrobial Therapy Against Resistant Gram-Negative Organisms: Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae, Carbapenem-Resistant Enterobacteriaceae, and Multidrug-Resistant Pseudomonas aeruginosa
- (2011) Souha S. Kanj et al. MAYO CLINIC PROCEEDINGS
- Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae
- (2010) David M. Livermore et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non- -Lactam -Lactamase Inhibitor
- (2010) T. Stachyra et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evaluation of Ceftazidime and NXL104 in Two Murine Models of Infection Due to KPC-ProducingKlebsiella pneumoniae
- (2010) Andrea Endimiani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multiresistant Gram-negative infections: a global perspective
- (2010) Jennifer Ho et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Activity of chequerboard combinations of ceftaroline and NXL104 versus -lactamase-producing Enterobacteriaceae
- (2010) S. Mushtaq et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Hospital-Acquired Infections Due to Gram-Negative Bacteria
- (2010) Anton Y. Peleg et al. NEW ENGLAND JOURNAL OF MEDICINE
- In vitro activity of the -lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases
- (2009) T. Stachyra et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum -lactamases and carbapenemases
- (2008) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now